Form 4: Elicio Therapeutics Director Acquires Stock Options

Allen Nissenson, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.

Summary

• Allen Nissenson, a director of Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.
• The exercise price of these options is $5.12 per share.
• The options vest fully on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date, provided Mr. Nissenson continues to provide services to the company.
• The options expire on November 21, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is neither particularly positive nor negative. It is a standard practice and does not indicate any significant change in the company's outlook.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The stock options will vest based on continued service and the timing of the next annual meeting.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of one year or the next annual meeting is also a typical arrangement.
• The 10-year expiration period is also standard for stock options.

Stakeholder Impact

• The stock option grant could potentially increase the director's alignment with shareholder interests.

Key Dates

Keywords

stock options, insider trading, director, Elicio Therapeutics, ELTX, equity